-- 独立研究机构CFRA向提供了以下研究报告。CFRA分析师总结如下:我们将12个月目标价从136美元上调至142美元,对应的市盈率为15倍,即2026财年每股收益9.51美元(高于此前预期的8.48美元;2027财年每股收益从9.62美元上调至10.20美元)。该市盈率高于12倍的长期平均水平,但更接近同行平均水平。我们认为,随着BG在收购Viterra后成为一家更加多元化的全球性企业,这一市盈率是合理的。在发布这份报告之前,市场预期较高,尤其是在近期美国出台利好的生物燃料政策之后。这一政策势头正在全球范围内蔓延,巴西、印度尼西亚和欧洲都在积极推进生物燃料的利用,部分原因是中东局势紧张导致原油价格上涨。我们对公司更新后的每股收益预期(从 7.50 美元至 8.00 美元提高到 9.00 美元至 9.50 美元)持乐观态度,并认为如果 2026 年下半年远期压榨利润率有所改善,则还有进一步上涨的潜力(目前的曲线反映了下半年的不确定性增加)。
Related Articles
Sector Update: Financial
Financial stocks were higher late Thursday afternoon, with the NYSE Financial Index rising 1.3% and the State Street Financial Select Sector SPDR ETF (XLF) up 0.5%.The Philadelphia Housing Index climbed 1.6%, and the State Street Real Estate Select Sector SPDR ETF (XLRE) added 1.5%.Bitcoin (BTC-USD) rose 0.9% to $76,409, and the yield for 10-year US Treasuries decreased 2.8 basis points to 4.39%.In corporate news, AvalonBay Communities (AVB) and Equity Residential (EQR) have held discussions over a potential merger, which would be one of the biggest real estate deals ever, Bloomberg reported. AvalonBay shares were down 1.1%, and Equity Residential was fractionally lower.
Market Chatter: Zuckerberg, Cook Not Exploring Seattle Seahawks Bid
Meta Platforms (META) CEO Mark Zuckerberg and Apple (AAPL) CEO Tim Cook are not pursuing a bid for the National Football League's Seattle Seahawks, Bloomberg reported on Thursday, citing company and industry sources.A Meta spokesperson said Zuckerberg is not making any investment or bid for the team, while a person familiar with Cook's plans denied his involvement, the report said.Meta and Apple did not immediately respond to requests for comment from.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $616.43, Change: $-52.69, Percent Change: -7.87%
Axsome Therapeutics Says FDA Approves Auvelity for Alzheimer's Disease Agitation
Axsome Therapeutics (AXSM) said Thursday the US Food and Drug Administration approved Auvelity for the treatment of agitation associated with Alzheimer's disease dementia.The approval was supported by two phase 3 clinical trials that showed the drug significantly improved agitation symptoms and resulted in a longer time to relapse compared with placebo.The medication acts on N-methyl-D-aspartate and sigma-1 receptors in the brain and is also approved for adults with major depressive disorder, the company added.Shares of Axsome were up more than 12% in Thursday trading.Price: $206.45, Change: $+22.50, Percent Change: +12.23%